Wayfinder Biosciences and Daiichi Sankyo Collaborate to Develop Novel RNA-Targeting Therapies for Neurodegenerative Disease

Wayfinder Biosciences, a biotech company developing RNA-targeting small molecules, has announced a collaboration with Daiichi Sankyo to pursue a key neurodegeneration target. Wayfinder’s platform uses proprietary RNA-based sensors and a data engine to discover potent, selective, and functional small molecules that bind directly to RNA, enabling therapies for previously “undruggable” targets.